Answers are grounded in this paper and cite their sources.
Therapy-induced senescence is increasingly recognized as a critical determinant of chemotherapy efficacy, tissue toxicity, and senolytic intervention. However, conventional senescence-associated β-galactosidase (SA-β-Gal) assays and single β-Gal-responsive probes often suffer from limited specificity because elevated β-Gal activity is not exclusive to senescent cells. Here, we report ECD-Gal, a dual-locked near-infrared fluorescent sensor that integrates β-Gal enzymatic activity with lysosomal pH variation for high-fidelity sensing therapy-induced senescence. ECD-Gal shows weak emission in β-Gal positive cells with an acidic lysosomal microenvironment but is strongly activated in senescent cells where β-Gal accumulation coincides with lysosomal alkalinization. Mechanistic studies using agents that induced lysosomal acidification or lysosomal alkalinization supported that both β-Gal activity and elevated lysosomal pH are required for fluorescence activation. ECD-Gal enabled confocal imaging, flow-cytometric quantification, in vivo visualization of doxorubicin or bleomycin-induced senescence, and its fluorescence readout correlated with SA-β-Gal staining, senescence marker expression, and fibrosis-associated pathological remodeling. This dual-locked sensing strategy provides a robust molecular tool for monitoring therapy-induced senescence and evaluating senolytic interventions in living systems.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: